Skip to main content
Vitrolife logo

Vitrolife — Investor Relations & Filings

Ticker · VITR ISIN · SE0011205202 LEI · 5493001WDZMONMSPPR49 ST Manufacturing
Open in API
Filings indexed 656 across all filing types
Latest filing 2009-01-14 M&A Activity
Country SE Sweden
Listing ST VITR

About Vitrolife

https://www.vitrolife.com/

Vitrolife is a global company focused on reproductive health, providing medical devices and genetic testing services primarily to In Vitro Fertilization (IVF) clinics. The company develops, produces, and markets a comprehensive portfolio of products and solutions that support the entire assisted reproduction treatment journey, from oocyte retrieval and sperm preparation to fertilization, embryo culture, evaluation, transfer, and cryopreservation. With a strong emphasis on quality control, innovation, and clinical support, Vitrolife aims to improve treatment outcomes and operational efficiency for its partners. The company also offers educational resources and training for professionals through its Vitrolife Academy.

Recent filings

Filing Released Lang Actions
M&A Activity 2009
M&A Activity Classification · 99% confidence The document is a press release dated January 14, 2009, announcing that Vitrolife AB intends to make a voluntary share exchange offer to acquire all outstanding shares in MediCult a/s. This action involves a proposed merger/takeover bid between two companies, detailing the terms of the offer (share exchange ratio, valuation, premium) and the strategic rationale (synergies, market position). This clearly falls under the definition of M&A Activity (TAR). It is not a formal regulatory filing like a 10-K, nor is it a simple announcement of a report (RPA/RNS), but rather the core announcement of a transaction proposal.
2009-01-14 Swedish
Board/Management Information 2008
Board/Management Information Classification · 99% confidence The document is a short press release dated December 19, 2008, announcing that 'Eva Nilsagård has been appointed as the new Head of Vitrolife's Accounting and Finance department and Investor Relations.' This explicitly details a change in senior management/personnel. This directly matches the definition for Board/Management Information (MANG). The document length is short (2905 chars), but it is the primary announcement itself, not an announcement *about* a report, so RPA/RNS is less appropriate than the specific content classification.
2008-12-19 English
Board/Management Information 2008
Board/Management Information Classification · 99% confidence The document is titled "Pressmeddelande" (Press Release) and announces the hiring of a new CFO ("Ny CFO på Vitrolife"). This type of announcement, concerning changes in senior management or the board of directors, directly corresponds to the definition of Board/Management Information (MANG). Although it is a press release, the core content is management change, not a general regulatory filing (RNS) or a report publication announcement (RPA), as it contains the substantive news itself, not just a notification that a report is available. The document length is short (2800 chars), but the content is specific to management change.
2008-12-19 Swedish
Regulatory Filings 2008
Regulatory Filings Classification · 95% confidence The document is explicitly labeled as a "Press release" dated December 5, 2008, announcing regulatory approval from the American Food and Drug Administration (FDA) for specific products. This is a general corporate announcement regarding a business development (product approval) rather than a mandatory periodic financial filing (like 10-K, IR, ER) or a specific shareholder communication (like DEF 14A, AGM-R). Since it does not fit into the specific categories like Earnings Release (ER), Interim Report (IR), or Capital Update (CAP), and it is a direct announcement of news, the most appropriate general category is Regulatory Filings (RNS), which serves as a broad category for miscellaneous regulatory or significant corporate news announcements that don't fit elsewhere, especially when the core content is a news update rather than a detailed financial report.
2008-12-05 English
Regulatory Filings 2008
Regulatory Filings Classification · 95% confidence The document is a short press release dated December 5, 2008, announcing that Vitrolife has received FDA approval in the USA for its embryo freezing products. It details the specific products (RapidVit™ Cleave and RapidWarm™ Cleave) and quotes management. This is a specific corporate announcement regarding product/regulatory milestones, not a comprehensive financial report (like 10-K or IR), a transcript (CT), or a general shareholder vote result (DVA). Since it is a specific announcement of a regulatory event (FDA approval), it fits best under the general 'Regulatory Filings' (RNS) category, as there is no specific code for 'Product Approval Announcement'. Given its nature as a news release about a significant event, RNS is the most appropriate fallback.
2008-12-05 Swedish
Interim / Quarterly Report 2008
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for the period January–September 2008 for Vitrolife AB. It contains detailed financial statements, including income statements, balance sheet data, cash flow analysis, and management commentary on business segments (Fertility, Transplantation, Stem Cell Culture). It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). 9M 2008
2008-10-22 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.